Pfizer and BioNTech announce a positive early update of Gerguy’s phase 1/2 study of the COVID-1nine vaccine, including the first T cell response data

Does Alin have an account? Identifying yourself

PfizerAmy Rose Media Relations – 1 (212) [email protected]

PfizerChuc Triano Investor Relations – 1 (212) [email protected]

BioNTech Press RelationsJasmina Alatovic – fournine (0) 6131 nine08four 1513 or ‘fournine (0) 151 1nine78 [email protected]

Investor Relations BioNTechSylke Maas, Ph.D. – fournine (0) 6131 nine08four [email protected]

Thank you for subscribing! If you have questions about Apple, call us at 1-877-440-ZING or email us at [email protected]